A carregar...
Update on the emerging role of telavancin in hospital-acquired infections
Telavancin is a lipoglycopeptide that has activity against Gram-positive aerobic and anaerobic bacteria. It has activity against methicillin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus and non-Van-A strains of vancomycin-resistant enterococci. It has been approved by the US Fo...
Na minha lista:
| Publicado no: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4403509/ https://ncbi.nlm.nih.gov/pubmed/25926737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S57376 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|